NCT02371967View on ClinicalTrials.gov

A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

April 8, 2015

Primary Completion Date

August 19, 2020

Study Completion Date

August 19, 2020

Conditions
Basal Cell Carcinoma
Interventions
DRUG

Vismodegib

Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.

Trial Locations (4)

41345

SU/Sahlgrenska, Hudkliniken, Gothenburg

222 41

Skånes Universitetssjukhus; Hudkliniken, Lund

171 64

Radiumhemmet, Solna

Unknown

Norrlands universitetssjukhus; Onkologkliniken, Umeå

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02371967 - A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC) | Biotech Hunter | Biotech Hunter